Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GJB2 | P29033 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AMY2A | P04746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13758175 | 0.89 | LGALS8 (0.47) | LGALS8LGALS3LGALS4GAAAMY2A | |
| SCHEMBL14768928 | 0.88 | LGALS8 (0.49) | LGALS8LGALS3LGALS4GAAAMY1A | |
| SCHEMBL14691142 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL19506512 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL9184494 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL15353311 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL14691208 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL2052804 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL8583827 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL15353310 | 0.86 | GAA (0.53) | LGALS8LGALS3LGALS4GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286250-A1 | FLUORINATED LIPIDS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286250-A1 | FLUORINATED LIPIDS AND METHODS OF USE | NPC1L1, SGMS2, SGMS1 | LGALS8 1022/4885LGALS3 971/4885LGALS4 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.